ArticleSexually transmitted diseases2026
An exploratory intersectional analysis of lifetime syphilis prevalence among people who inject drugs in Montreal, Canada.
Article in Sexually transmitted diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSyphilis cases have increased among women and heterosexual men in Canada and people who inject drugs (PWID) are an emerging group at risk of infection. We aimed to examine syphilis prevalence among PWID stratified by men and women, and differences according to intersecting population groups, socio-structural factors and sexual and substance use behaviors.
methodsData were from HEPCO, a community-based cohort study of PWID in Montreal. We tested for syphilis (lifetime and active) via treponemal testing reflexed to non-treponemal testing if positive. Odds ratios were estimated using bivariable exact logistic regression to examine differences in the prevalence of lifetime syphilis infection.
resultsFrom November 2022 to March 2024, 386 people (16.1% women) had a syphilis test. Thirty-three people (8.6%, 95%CI 6.1,11.8) had evidence of lifetime syphilis infection, of whom two had active syphilis. Lifetime prevalence was significantly higher among men identifying as gay or bisexual, men with HIV, and those who reported recent sex work, condom-less sex, 2 or more sex partners and amphetamine injecting. Among women, prevalence was higher among those who reported recent sex work, recent unstable housing and amphetamine injecting; however, there was no statistically significant difference.
conclusionActive syphilis infection was uncommon among this cohort of PWID; however, lifetime syphilis infection was almost 9%. Among men in this cohort, evidence indicates that syphilis intersects with other key population group characteristics. More data are needed to better understand syphilis among women who inject drugs. Periodic syphilis testing among PWID may be justified alongside testing for other sexually transmissible and blood borne infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.